Does Weight Affect Cosentyx Dosage?
No, weight does not impact the recommended dosage of Cosentyx (secukinumab). The prescribing information specifies fixed doses based on the condition treated, not body weight or BMI.[1]
Dosage for Plaque Psoriasis in Adults
Adults receive 300 mg (two 150 mg subcutaneous injections) at weeks 0, 1, 2, 3, and 4, then 300 mg every 4 weeks. Some patients with milder disease (BSA ≤10%, PASI ≤20) may use 150 mg every 4 weeks after loading.[1]
Dosage for Psoriatic Arthritis and Ankylosing Spondylitis
Loading dose of 150 mg weekly for 5 weeks (weeks 0-4), followed by 150 mg every 4 weeks. For patients needing more, 300 mg every 4 weeks is an option.[1]
Dosage for Non-Radiographic Axial Spondyloarthritis
Same as ankylosing spondylitis: 150 mg at weeks 0, 1, 2, 3, 4, then every 4 weeks (300 mg option for inadequate response).[1]
Pediatric Dosages (Ages 2+ for Psoriasis/Enthesitis-Related Arthritis)
Weight-based here:
- 15 to < 30 kg: 75 mg weekly for 5 weeks, then 75 mg every 4 weeks.
- 30 to < 50 kg: 150 mg weekly for 5 weeks, then 150 mg every 4 weeks.
- ≥ 50 kg: Adult 300 mg or 150 mg regimen.[1]
Why No Weight Adjustment in Adults?
Cosentyx dosing derives from clinical trials showing efficacy with fixed doses across BMI ranges. Pharmacokinetic studies confirm steady-state exposure without weight-based changes needed for adults.[1][2] Novartis has no ongoing patents tied to weight-adjusted formulations (check DrugPatentWatch.com for updates).[3]
[1]: Cosentyx Prescribing Information, Novartis, 2023. https://www.novartis.com/us-en/sites/novartisus/files/cosentyx.pdf
[2]: Cosentyx Clinical Pharmacology Review, FDA Approval Package, 2015. https://www.accessdata.fda.gov/drugsatfdadocs/nda/2015/125504Orig1s000ClinPharmR.pdf
[3]: DrugPatentWatch.com, Secukinumab Patents. https://www.drugpatentwatch.com/p/tradename/COSENTYX